Abstract
Introduction: Age-related macular degeneration (AMD) continues to be a leading cause of blindness worldwide. The neovascular form of the disease can lead to rapid and progressive vision loss. Vascular endothelial growth factor (VEGF) has emerged as a key target of treatment, with inhibitors of VEGF being shown to arrest the angiogenic process and avoid the visual damage typically associated with its presence.Areas covered: This manuscript reviews the treatment history for wet AMD and examines aflibercept, a new, fully human, recombinant fusion protein designed to bind all isoforms of VEGF-A, as well as placental growth factor (PGF), thereby inhibiting the binding and activation of VEGF receptors.Expert opinion: The results of Phase I, II and III studies have proven aflibercept to be a safe and effective treatment for wet AMD. Recent results of Phase III studies demonstrate the efficacy of aflibercept, dosed every 8 weeks after three initial monthly doses, and show that this regimen is clinically equivalent to monthly ranibizumab therapy. Eylea™ (aflibercept) was approved by the FDA for the treatment of wet AMD on 18 November 2011.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
